| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
MPL Mutation Analysis
MessageFor Specimen Integrity during Extreme Weather see the “Lockbox Usage in Extreme Weather” document at the top of this page.
Test Code
MPLMUT
Alias/See Also
92476
CPT Codes
81339<br>CPT coding may differ dependent on payer rules which may impact prior authorization testing.<br>Please direct any questions regarding CPT coding to the payer being billed.
Preferred Specimen
4 mL whole blood or 3 mL bone marrow aspirate collected in an EDTA (lavender-top) tube
Minimum Volume
3 mL whole blood • 1 mL bone marrow aspirate
Other Acceptable Specimens
Whole blood or bone marrow aspirate collected in: Sodium heparin (green-top) tube • Fixed-cell pellet collected in a plastic leak-proof container • Extracted DNA from CLIA-certified laboratory collected in a sterile leak-proof container
Instructions
Do not reject specimens, send to lab for screening.
Cell Pellets: Send fixed samples within 7 days of fixation date in a plastic, leak-proof tube/container. Indicate type of fixative used along with patient name, specimen source, date collected, and date harvested/fixed. Cell pellets submitted in Carnoy's or other alcohol-based fixatives are acceptable.
Cell Pellets: Send fixed samples within 7 days of fixation date in a plastic, leak-proof tube/container. Indicate type of fixative used along with patient name, specimen source, date collected, and date harvested/fixed. Cell pellets submitted in Carnoy's or other alcohol-based fixatives are acceptable.
Transport Temperature
Room temperature
Specimen Stability
Whole blood, bone marrow aspirate, Fixed cell pellets
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
Extracted DNA
Room temperature:7 days
Refrigerated: 1
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
Extracted DNA
Room temperature:7 days
Refrigerated: 1
Methodology
Next-Generation Sequencing
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 5-7 days
Clinical Significance
This advanced DNA-based, next-generation sequencing (NGS) assay analyses leukocytes from blood or bone marrow aspirate for mutations in exon 10 of the thrombopoietin receptor (MPL), including condons 505 and 515. Mutations at these sites in MPL are associated with myeloproliferative neoplasms (MPN), particularly essential thrombocythemia (ET) and primary myelofibrosis (PMF).
Performing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20153
